SynthesisBiomolecules2022
Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis.
Synthesis in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- The association between steatotic liver disease and chronic kidney disease: a meta-analysis and Mendelian randomization study highlighting metabolic comorbidities.Nutrition & diabetes · 2026Pooled it
- Association of noninvasive tests of liver fibrosis with chronic kidney disease in MASLD: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Liver fibrosis biomarkers as a prognostic tool beyond the defining components in cardiovascular-kidney-metabolic syndrome.American journal of preventive cardiology · 2026Article
- Metabolic Dysfunction-associated Steatotic Liver Disease and Chronic Kidney Disease: From Epidemiology and Pathophysiology to Clinical Prediction and Treatment Options.Journal of clinical and translational hepatology · 2026Review
- Investigating Factors Influencing Disease Progression in Patients With Non-Alcoholic Fatty Liver Disease.Journal of clinical medicine research · 2026Article
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- Estimated pulse wave velocity and dipstick proteinuria in young adults with MASLD: a cross-sectional health-check analysis.Frontiers in medicine · 2026Article
- The impact of metabolic dysfunction-associated steatotic liver disease (MASH) on the high risk of cardiovascular disease in CKD: interconnections and management.Clinical kidney journal · 2025Review
- Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD.Journal of clinical medicine · 2025Review
- Antioxidative Function of Zinc and Its Protection Against the Onset and Progression of Kidney Disease Due to Cadmium.Biomolecules · 2025Review
- Predicting the risk of metabolic-associated fatty liver disease in the elderly population in China: construction and evaluation of interpretable machine learning models.Frontiers in medicine · 2025Article
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025.Diabetes care · 2025Review
- Multimorbidity in elderly patients with or without T2DM: A real-world cross-sectional analysis based on primary care and hospitalisation data.Journal of global health · 2024Article
- Epicardial and liver fat implications in albuminuria: a retrospective study.Cardiovascular diabetology · 2024Article
- A Population-Based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia.The Journal of clinical endocrinology and metabolism · 2024Article
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective.World journal of gastroenterology · 2024Article
- Effect of MAFLD on albuminuria and the interaction between MAFLD and diabetes on albuminuria.Journal of diabetes · 2024Article
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2024.Diabetes care · 2024Review
- Article
- Associations of non-invasive indices of liver steatosis and fibrosis with progressive kidney impairment in adults with type 2 diabetes.Acta diabetologica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An association between liver stiffness, a surrogate measure of liver fibrosis, and chronic kidney disease (CKD) in patients with nonalcoholic fatty liver disease (NAFLD) has been proposed. However, most studies were small and had low statistical power. We systematically searched PubMed-MEDLINE and Scopus from inception to August 2021 for cross-sectional or cohort studies reporting the association between liver stiffness diagnosed by vibration controlled transient elastography (VCTE) and renal dysfunction. The primary outcome was CKD, defined as a composite of urinary albumin to creatinine ratio (UACR) ≥ 30 mg/g and estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.